300653.SHE Yantai Zhenghai Bio-Tech Co Ltd
- Market cap
- CNY 2.49B
- P/E
- 38.4x
- P/B
- 2.81x
- ROE
- 7.3%
- Dividend yield
- 3.28%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300653.SHE undervalued?
Graham number300653.SHE trades 118.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Yantai Zhenghai Bio-Tech Co Ltd fundamental analysis
No fundamental analysis for Yantai Zhenghai Bio-Tech Co Ltd yet.
Yantai Zhenghai Bio-Tech Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Yantai Zhenghai Bio-Tech Co Ltd
Yantai Zhenghai Biotechnology Co., Ltd. engages in the research and development, production, and sales of bioregenerative medical materials in China. The company offers oral restoration membranes, absorbable dura mater patches, active biological bones, skin repair membranes, bone repair materials, surgical packing sponges, phosphoric acid etching agent, dental pit and fissure sealant, active biological bone, light-curing composite resin, non-absorbable surgical sutures, and …
Full company profileYantai Zhenghai Bio-Tech Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Yantai Zhenghai Bio-Tech Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 151M | 183M | 216M | 280M | 293M | 400M | 433M | 414M | 363M | 364M | 308M |
| Gross Profit | 139M | 171M | 200M | 260M | 270M | 356M | 383M | 371M | 317M | 313M | 254M |
| Operating Income | 44.6M | 70.6M | 99.4M | 123M | 134M | 192M | 212M | 219M | 153M | 75.6M | 59.8M |
| EBITDA | 57.5M | 76.1M | 104M | 130M | 143M | 209M | 231M | 239M | 175M | 111M | 59.8M |
| Net Income | 45.5M | 61.7M | 85.8M | 107M | 118M | 169M | 185M | 191M | 135M | 82.4M | 64.6M |
| EPS | 0.34 | 0.38 | 0.48 | 0.59 | 0.66 | 0.94 | 1.28 | 1.06 | 0.75 | 0.46 | 0.36 |
| Balance Sheet | |||||||||||
| Total Assets | 259M | 531M | 584M | 720M | 806M | 929M | 987M | 1.05B | 980M | 985M | 976M |
| Total Liabilities | 31.0M | 47.6M | 55.0M | 132M | 159M | 144M | 122M | 106M | 91.3M | 95.1M | 88.1M |
| Shareholders' Equity | 228M | 483M | 529M | 588M | 647M | 785M | 865M | 948M | 889M | 889M | 888M |
| Cash & Short-term Investments | 104M | 98.7M | 132M | 453M | 445M | 572M | 617M | 675M | 622M | 62.0M | 55.7M |
| Total Debt | - | - | - | 22.3M | 26.4M | 13.3M | 25.1M | 18.0M | 5.16M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 49.2M | 65.5M | 77.5M | 103M | 118M | 166M | 188M | 180M | 151M | 97.2M | - |
| Capital Expenditure | 35.5M | 10.6M | 6.77M | 62.3M | 103M | 9.82M | 56.1M | 31.9M | 15.6M | 9.10M | 17.0M |
| Free Cash Flow | 13.7M | 54.9M | 70.7M | 41.2M | 15.4M | 156M | 132M | 149M | 136M | 88.1M | 44.2M |
| Ratios | |||||||||||
| ROE | 19.9% | 12.8% | 16.2% | 18.3% | 18.3% | 21.5% | 21.4% | 20.1% | 15.1% | 9.3% | 7.3% |
| ROA | 17.5% | 11.6% | 14.7% | 14.9% | 14.7% | 18.1% | 18.8% | 18.1% | 13.7% | 8.4% | 6.6% |
| Net Profit Margin | 30.2% | 33.7% | 39.8% | 38.4% | 40.3% | 42.1% | 42.8% | 46.2% | 37.1% | 22.6% | 21.0% |
| Debt to Equity | - | - | - | 0.04x | 0.04x | 0.02x | 0.03x | 0.02x | 0.01x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Yantai Zhenghai Bio-Tech Co Ltd dividends
- Dividend yield
- 3.28%
- Forward dividend
- 0.28 CNY
- Payout ratio
- 99.2%
- Ex-dividend date
- May 27, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 81.7M | 0.45 | 99.2% |
| 2024 | CNY 144M | 0.80 | 107.0% |
| 2023 | CNY 108M | 0.60 | 56.6% |
| 2022 | CNY 106M | 0.73 | 56.9% |
| 2021 | CNY 30.0M | 0.17 | 17.8% |
| 2020 | CNY 60.1M | 0.34 | 50.8% |
| 2019 | CNY 48.0M | 0.27 | 44.7% |
| 2018 | CNY 40.0M | 0.22 | 46.6% |
| 2017 | CNY 40.0M | 0.25 | 64.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.5:1 on May 19, 2022.
Who owns Yantai Zhenghai Bio-Tech Co Ltd
- Insiders 44.91%
- Institutions 2.40%
- Public & others 52.69%
- Shares outstanding 180M
- Free float 108M
Yantai Zhenghai Bio-Tech Co Ltd company profile
- Company name
- Yantai Zhenghai Bio-Tech Co Ltd
- Ticker
- 300653.SHE
- ISIN
- CNE100002NZ1
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 379
- Fiscal year end
- December
- Address
- No. 7 Nanjing Street, Yantai, China, 264006
- Phone
- 86 53 5697 1993
- Website
- zhbio.com
About Yantai Zhenghai Bio-Tech Co Ltd
Yantai Zhenghai Biotechnology Co., Ltd. engages in the research and development, production, and sales of bioregenerative medical materials in China. The company offers oral restoration membranes, absorbable dura mater patches, active biological bones, skin repair membranes, bone repair materials, surgical packing sponges, phosphoric acid etching agent, dental pit and fissure sealant, active biological bone, light-curing composite resin, non-absorbable surgical sutures, and self-etching adhesives. Its products are used in various fields, such as dentistry, orthopedics, neurosurgery, and trauma surgery. Yantai Zhenghai Biotechnology Co., Ltd. was founded in 2003 and is headquartered in Yantai, China.
Yantai Zhenghai Bio-Tech Co Ltd management
5- Mr. Kan SongGM & Director · born 1984
- Mr. Donggang ZhangDeputy GM & Employee Representative Director · born 1976
- Ms. Li ZhaoDeputy GM, Secretary & Non-Independent Director · born 1979
- Mr. Xing YangDeputy General Manager · born 1976
- Xiao Ning Sheng ZhangAccounting Supervisor